Sertraline for Anxiety Disorders
(EV-SoPRANO Trial)
Trial Summary
What is the purpose of this trial?
A Multicenter, acute, randomized, double-blind, placebo-controlled, flexible-dose trial with the treatment of sertraline.
Will I have to stop taking my current medications?
The trial requires that participants have not used SSRIs (a type of antidepressant) within 12 weeks before starting the study and not be on medications affecting the central nervous system that need more than five half-lives to stop. This means you may need to stop certain medications before joining the trial.
What data supports the effectiveness of the drug sertraline for anxiety disorders?
Is sertraline generally safe for humans?
Sertraline, also known as Zoloft, has been shown to be safe for treating various conditions like depression, anxiety, and panic disorders. It is generally well-tolerated, but like all medications, it can have side effects. Studies have evaluated its safety in different settings, confirming its safety profile in humans.45678
How does the drug sertraline differ from other treatments for anxiety disorders?
Sertraline is unique because it is a selective serotonin reuptake inhibitor (SSRI) that has been extensively tested and proven effective for various anxiety disorders, including panic disorder and social anxiety, with a well-tolerated safety profile. It is comparable to other medications and therapies, such as cognitive behavioral therapy, and is considered a first choice among SSRIs for panic disorder due to its efficacy and tolerability.345910
Research Team
Jeffrey R Strawn, MD, FAACAP
Principal Investigator
University of Cincinnati
Eligibility Criteria
This trial is for children and teens aged 8-17 with generalized, social, or separation anxiety disorders. They must be able to use contraception if sexually active, have no major psychiatric or neurological conditions other than anxiety, not be on certain medications recently, and commit to the study schedule.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive sertraline or placebo for 12 weeks, with plasma EVs collected at baseline and serially
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Sertraline (Selective Serotonin Reuptake Inhibitor)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Cincinnati
Lead Sponsor
Dr. Greg Postel
University of Cincinnati
Chief Medical Officer since 2020
MD from Indiana University School of Medicine
Dr. Neville G. Pinto
University of Cincinnati
Chief Executive Officer since 2017
PhD in Chemistry from the University of Virginia
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Dr. Diana W. Bianchi
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Chief Executive Officer since 2016
MD from Stanford University
Dr. Alison Cernich
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Chief Medical Officer since 2020
PhD in Clinical Psychology from University of Maryland